Vanguard reports 0 shares of Elanco after realignment (NYSE: ELAN)
Rhea-AI Filing Summary
Elanco Animal Health Inc amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares of Elanco common stock. The filing states that Vanguard completed an internal realignment on January 12, 2026, after which certain subsidiaries report beneficial ownership separately. The form is signed by Ashley Grim on 03/26/2026.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did The Vanguard Group report for ELAN in this Schedule 13G/A?
The Vanguard Group reported 0 shares of Elanco Animal Health Inc. The filing states Vanguard now reports certain subsidiaries separately following an internal realignment on January 12, 2026.
Why does Vanguard show zero beneficial ownership for ELAN?
Vanguard explains an internal realignment on January 12, 2026, after which subsidiaries or business divisions report beneficial ownership separately in reliance on SEC Release No. 34-39538.
Who signed the Schedule 13G/A amendment for ELAN?
The filing is signed by Ashley Grim, Head of Global Fund Administration. The signature date on the form is 03/26/2026.
What address is listed for The Vanguard Group in the ELAN filing?
The filing lists The Vanguard Group's address as 100 Vanguard Blvd., Malvern, PA, 19355. The issuer address for Elanco is listed as 2500 Innovation Way, Greenfield, IN, 46140.